# Clinical Cases: Adolescent Medicine ## Case 1: Adolescent Type 1 Diabetes Management ### Patient Presentation **Demographics:** 15-year-old female high school sophomore, competitive swimmer **Chief Complaint:** "I've been losing weight even though I'm eating more, and I'm always thirsty and going to the bathroom all the time." **History of Present Illness:** The patient presents to the adolescent medicine clinic with her mother with a four-week history of progressive polyuria, polydipsia, and unintentional weight loss of approximately 5 kg (11 lbs). She reports drinking up to 4 liters of water per day and waking 3-4 times nightly to urinate, which has begun affecting her school performance and swim practice. She describes persistent fatigue that has worsened over the past two weeks, causing her to miss several swim practices — something very unusual for this previously highly motivated athlete. Her mother noticed that her daughter appeared thinner and more fatigued than usual. The patient also reports intermittent blurred vision for the past week, mild nausea without vomiting, and one episode of a vaginal yeast infection two weeks ago (treated with over-the-counter antifungal). She denies abdominal pain, fever, cough, recent illnesses, or any substance use. She denies any intentional caloric restriction or excessive exercise beyond her swim training. The patient is concerned that her declining performance in the pool and academic difficulties will jeopardize her chances for a college swimming scholarship. She reports feeling "frustrated and scared" about her symptoms. **Past Medical History:** - No prior chronic illnesses - Full immunization schedule up to date - Menarche at age 12; regular menstrual periods until 2 months ago (has missed last 2 cycles) - No prior hospitalizations or surgeries - No known drug allergies **Medications:** - None (other than recent OTC miconazole for yeast infection) **Social History:** - 10th grade student, honor roll (grades declining over the past month) - Competitive swimmer since age 8; practices 6 days per week, 2 hours daily - Lives with both parents and a 12-year-old brother - Denies tobacco, alcohol, drug use, or sexual activity (HEADSS assessment completed) - No recent travel - Good peer relationships; reports no bullying - Screen time approximately 2 hours daily on weekdays **Family History:** - Mother: Hashimoto's thyroiditis (on levothyroxine) - Maternal grandmother: type 1 diabetes (diagnosed at age 22) - Father: healthy - Paternal grandfather: type 2 diabetes - Brother: healthy, no autoimmune conditions ### Physical Examination - **Vital Signs:** BP 108/68 mmHg, HR 94 bpm (mild tachycardia), RR 18/min, Temp 36.7°C, Weight 52 kg (down from 57 kg at last sports physical 3 months ago), Height 165 cm, BMI 19.1 kg/m² (decreased from 20.9) - **General:** Alert, cooperative adolescent female; appears thin and mildly dehydrated; no acute distress; Tanner stage IV - **HEENT:** Dry mucous membranes; no thyromegaly; no oral thrush; slight fruity odor to breath - **Cardiovascular:** Tachycardic, regular rhythm, no murmurs; capillary refill 2.5 seconds - **Respiratory:** Clear to auscultation bilaterally; no Kussmaul breathing - **Abdomen:** Soft, non-tender, non-distended; no hepatosplenomegaly - **Skin:** Dry skin with reduced turgor; no acanthosis nigricans; no lipodystrophy; no rashes - **Neurological:** Alert and oriented x 3; cranial nerves intact; normal reflexes; no peripheral neuropathy - **Musculoskeletal:** Normal muscle bulk for an athlete; no joint swelling - **Psychological assessment:** PHQ-A score 8 (mild depression); reports sadness about physical changes and performance decline; denies suicidal ideation ### Workup and Results **Laboratory Studies:** | Test | Result | Reference Range | |------|--------|-----------------| | Random plasma glucose | 382 mg/dL | 70-140 mg/dL | | HbA1c | 11.2% | <5.7% (normal); >6.5% (diabetes) | | C-peptide (fasting) | 0.18 ng/mL | 0.8-3.1 ng/mL (low, indicating insulin deficiency) | | GAD65 antibodies | >250 IU/mL (positive) | <5 IU/mL | | IA-2 antibodies | 128 IU/mL (positive) | <7.5 IU/mL | | Zinc transporter 8 (ZnT8) antibodies | Positive | Negative | | Insulin autoantibodies (IAA) | Positive | Negative | | Blood pH (venous) | 7.31 | 7.35-7.45 | | Serum bicarbonate | 18 mEq/L | 22-28 mEq/L | | Urine ketones | Large (3+) | Negative | | Beta-hydroxybutyrate | 3.8 mmol/L | <0.6 mmol/L | | Serum sodium | 133 mEq/L | 136-145 mEq/L (corrected Na: 137) | | Serum potassium | 4.8 mEq/L | 3.5-5.0 mEq/L | | BUN | 22 mg/dL | 7-20 mg/dL (mild dehydration) | | Creatinine | 0.8 mg/dL | 0.5-1.0 mg/dL | | TSH | 3.2 mIU/L | 0.5-4.5 mIU/L | | Free T4 | 1.1 ng/dL | 0.8-1.8 ng/dL | | Anti-TPO antibodies | 48 IU/mL (mildly elevated) | <35 IU/mL | | Celiac panel (tTG-IgA) | 8 U/mL (negative) | <20 U/mL | | Total IgA | 180 mg/dL | 70-400 mg/dL (rules out IgA deficiency) | | Lipid panel | Total cholesterol 198, LDL 122, HDL 48, TG 140 | Dyslipidemia common in uncontrolled T1D | **Imaging/Additional Studies:** - **Point-of-care glucose confirmation:** 378 mg/dL (consistent with laboratory value) - **Urinalysis:** Glucosuria (4+), ketonuria (3+), pH 5.0, no leukocytes - **ECG:** Sinus tachycardia at 94 bpm, normal axis, no peaked T-waves (potassium within normal range) ### Clinical Image ![Diagram showing autoimmune pathophysiology of Type 1 diabetes and beta cell destruction](case_01_image.jpg) *Educational diagram illustrating the autoimmune pathophysiology of Type 1 diabetes mellitus, showing immune-mediated beta cell destruction, relevant autoantibodies, and the clinical consequences of insulin deficiency. Source: Educational illustration.* ### Diagnosis **New-Onset Type 1 Diabetes Mellitus with Mild Diabetic Ketoacidosis (DKA)** **Key Diagnostic Criteria:** - Classic symptoms: polyuria, polydipsia, unintentional weight loss, fatigue - Random plasma glucose >200 mg/dL (382 mg/dL) with symptoms — diagnostic of diabetes - HbA1c 11.2% — confirms chronic hyperglycemia over the preceding 2-3 months - Low C-peptide (0.18 ng/mL) — confirms endogenous insulin deficiency - Multiple positive autoantibodies (GAD65, IA-2, ZnT8, IAA) — confirms autoimmune etiology (Type 1) - Mild DKA: pH 7.31, bicarbonate 18, elevated beta-hydroxybutyrate, ketonuria - Family history of autoimmune disease (maternal Hashimoto's, maternal grandmother T1D) - Elevated anti-TPO antibodies indicating risk of future thyroid autoimmunity (autoimmune polyendocrine syndrome screening) ### Treatment Plan 1. **Acute management of mild DKA:** - IV normal saline bolus 10 mL/kg over 1 hour, then maintenance fluids - Start IV insulin infusion at 0.05-0.1 units/kg/hour (no bolus needed for mild DKA) - Monitor blood glucose hourly; add dextrose to IV fluids when glucose falls below 250 mg/dL - Monitor electrolytes every 2 hours; supplement potassium as needed - Transition to subcutaneous insulin once DKA resolved (pH >7.3, bicarbonate >15, tolerating oral intake, anion gap closed) 2. **Initiation of basal-bolus insulin regimen:** - Basal insulin: Glargine (Lantus) 0.3-0.4 units/kg/day (starting dose ~18 units at bedtime) - Bolus insulin: Lispro (Humalog) with meals using insulin-to-carbohydrate ratio of 1:15 and correction factor of 1:50 (starting estimates; will be refined) - Alternative: Insulin pump therapy to be discussed after initial stabilization and education (may benefit her athletic schedule) 3. **Diabetes education program (multidisciplinary, over the first 2 weeks):** - Blood glucose monitoring: minimum 4 times daily (before meals and bedtime); discuss continuous glucose monitoring (CGM) with Dexcom G7 or Libre 3 - Carbohydrate counting education with a registered dietitian - Insulin injection technique training (rotation of injection sites) - Hypoglycemia recognition and treatment (Rule of 15: 15 g fast-acting carbohydrate, recheck in 15 minutes) - Glucagon emergency kit training for parents - Sick-day management rules - Exercise management: reducing bolus insulin by 25-50% before swimming; carrying glucose tablets to practice 4. **Psychosocial support:** - Psychology referral for adjustment to chronic illness diagnosis in an adolescent - Screen for diabetes distress at each visit - Connect with peer support (diabetes camp, online adolescent T1D communities) - School 504 plan to accommodate blood glucose monitoring, snacks, and bathroom access 5. **Screening for associated autoimmune conditions:** - Thyroid function monitoring annually (given elevated anti-TPO) - Celiac screening annually for the first 4 years, then as clinically indicated - Adrenal insufficiency screening if symptoms develop 6. **Follow-up schedule:** - Endocrinology within 1 week of discharge - Telephone/telehealth check-in within 48-72 hours for insulin dose adjustments - HbA1c every 3 months; target <7.0% (with individualization to avoid hypoglycemia) - Annual dilated eye examination beginning 5 years after diagnosis (or at age 11, whichever is later) - Annual urine microalbumin screening beginning 5 years after diagnosis ### Key Learning Points - Type 1 diabetes can present at any age but has a bimodal peak in childhood (ages 4-6 and 10-14); adolescent presentations may be initially missed or attributed to stress, growth spurts, or eating disorders. - Multiple autoantibody testing (GAD65, IA-2, ZnT8, IAA) increases diagnostic sensitivity for autoimmune T1D to >95%; a low C-peptide level confirms endogenous insulin deficiency and distinguishes T1D from T2D. - Adolescents with new-onset T1D are at high risk for associated autoimmune conditions, particularly thyroid disease (up to 30% prevalence) and celiac disease (5-8%); systematic screening is essential. - Exercise management is one of the most challenging aspects of T1D in athletic adolescents; swimming poses unique challenges as the pump must be disconnected, and hypoglycemia risk is increased by the exercise-induced improvement in insulin sensitivity. - The psychosocial impact of T1D diagnosis in adolescence is significant; adherence challenges peak during adolescence due to developmental needs for autonomy, peer belonging, and identity formation. A multidisciplinary approach including psychology support improves outcomes. --- ## Case 2: Eating Disorder — Bulimia Nervosa ### Patient Presentation **Demographics:** 17-year-old female high school junior, member of the dance team **Chief Complaint:** "My mom made me come in. She found out I've been throwing up after meals." **History of Present Illness:** The patient is brought to the adolescent medicine clinic by her mother, who discovered her daughter self-inducing vomiting after dinner three days ago. When confronted, the patient initially denied it but subsequently admitted to a pattern of binge eating followed by purging that began approximately 8 months ago. She describes episodes occurring 4-5 times per week, typically in the evening after school or after stressful events. During binge episodes, she consumes large quantities of food — typically entire boxes of cereal, bags of chips, ice cream, and cookies — in a rapid, uncontrollable fashion, usually within a 1-2 hour period while home alone. She describes a sense of loss of control during these episodes and profound shame afterward. She induces vomiting by inserting her fingers into her throat, usually within 30 minutes of the binge. She also reports misusing over-the-counter laxatives (bisacodyl) 2-3 times per week to "get rid of" remaining food and intermittently restricting her intake on non-binge days to 800-1000 calories. The behavior began after a dance team coach commented on her appearance, saying she "looked like she had gained weight over the summer" in front of her teammates. She reports preoccupation with body shape and weight, weighing herself 3-5 times daily, and feeling that her self-worth is primarily determined by her appearance. She has maintained a relatively stable weight, which she notes with frustration, as her goal is to lose "at least 10 more pounds." She reports recent episodes of dizziness upon standing, intermittent heart palpitations, heartburn, sore throat, and swollen cheeks. She admits to fatigue and difficulty concentrating in school. She denies suicidal ideation but acknowledges feeling "worthless" and "disgusted with myself" at times. **Past Medical History:** - No chronic illnesses - No prior psychiatric history or eating disorder diagnosis - Menarche at age 13; regular periods until 3 months ago (now irregular) - No hospitalizations or surgeries - Wisdom teeth removed at age 16 **Medications:** - Bisacodyl (OTC stimulant laxative) — 2-3 tablets, 2-3 times per week - No prescription medications - No supplements **Social History:** - 11th grade student; previously excellent student (GPA 3.8), grades declining this semester - Member of the school dance team (practices 5 days/week, performances monthly) - Lives with mother, stepfather, and 8-year-old half-sister - Parents divorced when she was 10; describes this as a "difficult time" - Denies tobacco, alcohol, or drug use - Denies current sexual activity; had one previous sexual partner; used condoms - Active social media use (Instagram, TikTok) — follows multiple "fitness" and "body transformation" accounts - Reports 2-3 close friends but has been socially withdrawing over the past 3 months - HEADSS assessment: positive for body image concerns, social withdrawal, and academic decline **Family History:** - Mother: history of depression, treated with SSRI - Maternal aunt: anorexia nervosa in her 20s (hospitalized) - Father: alcohol use disorder - No family history of thyroid disease or metabolic disorders ### Physical Examination - **Vital Signs:** BP 98/62 mmHg (supine), 82/54 mmHg (standing — orthostatic), HR 58 bpm (supine), 82 bpm (standing — orthostatic), RR 16/min, Temp 36.2°C, Weight 56.8 kg, Height 168 cm, BMI 20.1 kg/m² (25th percentile for age) - **General:** Alert, cooperative but guarded adolescent female; appears stated age; makes limited eye contact; Tanner stage V - **HEENT:** - Bilateral parotid gland enlargement (non-tender, firm) - Dental erosion on the lingual surfaces of upper incisors and premolars (perimolysis); several carious teeth - Pharyngeal erythema; soft palate petechiae - Dry mucous membranes - Subconjunctival hemorrhage in the left eye (likely from forceful vomiting) - **Cardiovascular:** Bradycardic but regular rhythm; no murmurs; orthostatic changes as noted above - **Abdomen:** Mild epigastric tenderness; no distension; bowel sounds present and hyperactive; no hepatosplenomegaly - **Extremities:** Cool peripherally; calluses on the dorsal surface of the right index and middle finger metacarpophalangeal joints (Russell sign) - **Skin:** Dry skin; mild lanugo-like hair on forearms; no bruising; no self-harm scars - **Neurological:** Alert and oriented; mild difficulty with concentration; cranial nerves intact; DTRs 1+ globally (hyporeflexia) ### Workup and Results **Laboratory Studies:** | Test | Result | Reference Range | |------|--------|-----------------| | Sodium | 139 mEq/L | 136-145 mEq/L | | Potassium | 2.9 mEq/L | 3.5-5.0 mEq/L (**hypokalemia**) | | Chloride | 92 mEq/L | 98-106 mEq/L (**hypochloremia**) | | Bicarbonate | 32 mEq/L | 22-28 mEq/L (**metabolic alkalosis**) | | BUN | 24 mg/dL | 7-20 mg/dL (dehydration) | | Creatinine | 0.7 mg/dL | 0.5-1.0 mg/dL | | Glucose | 72 mg/dL | 70-100 mg/dL | | Magnesium | 1.6 mg/dL | 1.8-2.4 mg/dL (**low**) | | Phosphorus | 2.8 mg/dL | 2.5-4.5 mg/dL (low-normal) | | Calcium | 9.2 mg/dL | 8.5-10.5 mg/dL | | Albumin | 3.9 g/dL | 3.5-5.0 g/dL | | Amylase | 210 U/L | 30-110 U/L (**elevated** — salivary origin from parotid enlargement) | | Lipase | 38 U/L | 0-160 U/L (normal — confirms salivary, not pancreatic, amylase) | | TSH | 2.8 mIU/L | 0.5-4.5 mIU/L | | CBC | WBC 5.2, Hgb 12.8, Plt 210 | Within normal limits | | Urine specific gravity | 1.028 | 1.005-1.030 (concentrated, dehydration) | | Urine drug screen | Negative | -- | | Beta-hCG | Negative | -- | | ESR | 6 mm/hr | 0-20 mm/hr | **Imaging/Additional Studies:** - **ECG:** Sinus bradycardia at 58 bpm; prolonged QTc interval at 478 ms (normal <460 ms for females); flattened T-waves in leads V2-V4; presence of U-waves — changes consistent with hypokalemia - **DEXA scan (to be ordered):** Recommended to assess bone mineral density given menstrual irregularity and nutritional compromise ### Clinical Image ![Diagram showing medical complications of bulimia nervosa across organ systems](case_02_image.jpg) *Educational diagram illustrating the multi-system medical complications of bulimia nervosa, including electrolyte disturbances, dental erosion, parotid enlargement, cardiac arrhythmias, esophageal injury, and metabolic alkalosis. Source: Educational illustration.* ### Diagnosis **Bulimia Nervosa, Purging Type — Moderate Severity (8-13 episodes per week) with Medical Complications** **Key Diagnostic Criteria (DSM-5):** - Recurrent episodes of binge eating: consuming an objectively large amount of food in a discrete time period with a sense of loss of control (criterion A) - Recurrent inappropriate compensatory behaviors: self-induced vomiting, laxative misuse, caloric restriction (criterion B) - Binge eating and compensatory behaviors occur at least once per week for 3 months — this patient exceeds this threshold at 4-5 times per week for 8 months (criterion C) - Self-evaluation is unduly influenced by body shape and weight (criterion D) - Disturbance does not occur exclusively during episodes of anorexia nervosa (criterion E) — BMI is 20.1, within normal range - Severity: moderate (4-7 compensatory behavior episodes per week; she reports 4-5 purging plus 2-3 laxative misuse episodes) **Medical Complications Present:** - Hypokalemic, hypochloremic metabolic alkalosis (from vomiting — loss of HCl) - Prolonged QTc interval (478 ms) — arrhythmia risk - Hypomagnesemia - Orthostatic hypotension with tachycardia (dehydration) - Parotid gland hypertrophy (sialadenosis) - Dental erosion (perimolysis) - Russell sign (knuckle calluses from self-induced vomiting) - Amenorrhea (hypothalamic — 3 months) ### Treatment Plan 1. **Acute medical stabilization (hospitalization criteria met):** - Admit to the adolescent medicine unit given: hypokalemia (K 2.9), prolonged QTc (478 ms), orthostatic hypotension, and bradycardia - Continuous cardiac monitoring until QTc normalizes - IV potassium replacement: KCl 40 mEq IV over 4 hours, then reassess; target K >3.5 mEq/L - Oral magnesium supplementation: magnesium oxide 400 mg twice daily - IV fluid resuscitation: normal saline 1 L over 4 hours, then reassess - Monitor electrolytes every 6-8 hours during repletion - Strict intake and output; supervised meals to prevent purging (1:1 observation for 1 hour after meals) - Repeat ECG after potassium normalization 2. **Nutritional rehabilitation:** - Registered dietitian consultation: establish regular meal pattern (3 meals, 2-3 snacks daily) - Discontinue laxative misuse with gradual taper (not abrupt cessation, to prevent rebound constipation) - Begin with 1500-1800 kcal/day and advance; refeeding syndrome risk is lower in BN than AN but should be monitored (electrolytes, especially phosphorus) 3. **Psychotherapy (cornerstone of treatment):** - Cognitive-behavioral therapy for bulimia nervosa (CBT-BN): first-line evidence-based treatment; typically 20 sessions over 5 months - Address body image distortions, cognitive distortions about weight and self-worth, and develop alternative coping strategies for emotional regulation - Family-based treatment (FBT) component: engage mother in meal support and monitoring 4. **Pharmacotherapy:** - Fluoxetine 20 mg daily, titrate to 60 mg (FDA-approved for BN in adults; commonly used in adolescents off-label); target dose of 60 mg is higher than the typical antidepressant dose - Rationale: reduces binge-purge frequency by 50-70% in conjunction with CBT - Monitor for SSRI side effects and suicidality (black box warning in adolescents) 5. **Dental referral:** Comprehensive dental evaluation and treatment plan for erosion and caries; advise against brushing immediately after vomiting (worsens erosion); use sodium bicarbonate rinse instead 6. **Follow-up:** - Weekly weight monitoring (in gown, facing away from scale — to reduce weight fixation) - Electrolytes weekly until stable, then monthly - ECG repeat after electrolyte normalization - DEXA scan at 6 months if amenorrhea persists - Menstrual function monitoring — expect return with nutritional improvement ### Key Learning Points - Bulimia nervosa patients are often of normal weight, making the diagnosis less visually apparent than anorexia nervosa; a high index of suspicion is needed, especially in adolescents involved in appearance-focused activities (dance, gymnastics, figure skating, wrestling). - The characteristic electrolyte pattern in purging-type bulimia is hypokalemic, hypochloremic metabolic alkalosis due to loss of gastric acid (HCl); in contrast, laxative misuse causes a non-anion-gap metabolic acidosis with hypokalemia. - A prolonged QTc interval (>460 ms in females, >450 ms in males) is a medical emergency in eating disorders because it predisposes to torsades de pointes and sudden cardiac death; potassium and magnesium must be repleted urgently. - CBT specifically adapted for bulimia nervosa (CBT-BN) is the most effective treatment, with 40-60% of patients achieving full remission; fluoxetine at 60 mg/day is the only FDA-approved medication and works synergistically with psychotherapy. - Russell sign (calluses on the dorsal knuckles from contact with teeth during self-induced vomiting), parotid enlargement, and dental perimolysis are classic physical examination findings that should prompt confidential inquiry about eating disorder behaviors in adolescents. --- ## Case 3: Adolescent Contraception Counseling ### Patient Presentation **Demographics:** 16-year-old female high school student **Chief Complaint:** "I want to go on birth control. I don't want my parents to know." **History of Present Illness:** The patient presents alone to the adolescent medicine clinic requesting contraception. She reports that she has been in a relationship with her 17-year-old boyfriend for the past 6 months and they have been sexually active for the past 2 months. They have been using condoms inconsistently — she estimates condom use approximately 50% of the time. She reports one episode of unprotected intercourse 4 days ago and is concerned about pregnancy, though her last menstrual period was 10 days ago (Day 14 of her cycle). She has done her own research online and is interested in "the implant" (etonogestrel subdermal implant) because a friend told her it lasts for years and she "won't have to remember to take a pill every day." She explicitly requests confidentiality and does not want her parents informed. She states that she fears her parents, who are "very conservative and religious," would "disown" her if they learned she was sexually active. She denies any pressure to have sex, abuse, or coercion by her partner. She reports the relationship is "healthy and equal." She has not previously used any form of hormonal contraception. She reports no history of sexually transmitted infections (STIs). She has never been pregnant. She has no other medical concerns at this visit. **Past Medical History:** - Migraine with aura (2-3 episodes per year since age 13; visual aura with scintillating scotoma preceding unilateral headache) - Mild intermittent asthma (well controlled, uses albuterol PRN rarely) - No surgical history - No known drug allergies - Menarche at age 12; regular cycles, 28-30 day intervals, 4-5 day duration, moderate flow, mild dysmenorrhea managed with ibuprofen **Medications:** - Albuterol MDI as needed (used <1x per month) - Ibuprofen as needed for menstrual cramps and migraines - No hormonal medications **Social History:** - 11th grade student, GPA 3.5 - Part-time job at a retail store (weekends) - Lives with both biological parents and a 13-year-old sister - One sexual partner (current boyfriend, age 17); vaginal intercourse only; no anal or oral intercourse - Condom use approximately 50% of the time - Denies tobacco, alcohol, or drug use - No history of sexual abuse, coercion, or dating violence (screened with validated tool) - Appears emotionally mature and well-informed for her age - HEADSS assessment: no red flags identified beyond the current contraceptive need **Family History:** - Mother: hypertension, history of blood clots in the leg after surgery (provoked DVT at age 42) - Father: type 2 diabetes - Maternal grandmother: stroke at age 68 - No known thrombophilias tested in the family ### Physical Examination - **Vital Signs:** BP 112/72 mmHg, HR 74 bpm, RR 16/min, Temp 36.6°C, Weight 62 kg, Height 163 cm, BMI 23.3 kg/m² - **General:** Well-appearing, well-nourished adolescent female; Tanner stage V; appears comfortable; no acute distress - **Cardiovascular:** Regular rate and rhythm; no murmurs - **Abdomen:** Soft, non-tender, non-distended; no masses - **Skin:** No acne; no hirsutism; no skin changes suggestive of hormonal abnormalities - **No pelvic examination performed** (not required for contraception initiation per ACOG guidelines) - **Extremities:** No edema, no varicosities, no signs of deep vein thrombosis ### Workup and Results **Laboratory Studies:** | Test | Result | Reference Range | |------|--------|-----------------| | Urine beta-hCG | Negative | -- | | Urine dipstick | Normal | -- | | Chlamydia NAAT (urine) | Pending | -- | | Gonorrhea NAAT (urine) | Pending | -- | | HIV 4th generation Ag/Ab | Pending | -- | | RPR (syphilis screening) | Pending | -- | | Blood pressure | 112/72 mmHg | Normal for age | **Imaging/Additional Studies:** - None required for contraception counseling and initiation - Pelvic examination not indicated (ACOG and AAP guidelines state that pelvic examination is not required prior to initiating contraception, including IUDs and implants in adolescents) ### Clinical Image ![Comparison chart of contraceptive methods showing effectiveness, duration, and suitability for adolescents](case_03_image.jpg) *Educational chart comparing long-acting reversible contraceptive (LARC) methods and other contraceptive options for adolescents, including effectiveness rates, duration, advantages, and contraindications. Source: Educational illustration.* ### Diagnosis **Reproductive Health Visit: Contraception Counseling in an Adolescent with Migraine with Aura** **Key Diagnostic Criteria:** - Sexually active adolescent requesting contraception — appropriate and timely clinical encounter - Migraine with aura — **absolute contraindication (USMEC Category 4) to combined hormonal contraceptives** (combined oral contraceptives, patch, ring) due to elevated risk of ischemic stroke - Family history of provoked DVT (mother) — low risk but warrants consideration; thrombophilia testing not routinely indicated for provoked DVT in a family member - Confidentiality request — all 50 US states and DC allow minors to consent to contraceptive services without parental consent; specific laws vary by state - Recent unprotected intercourse 4 days ago at Day 14 of cycle — emergency contraception should be discussed, though within the fertile window, pregnancy test is negative ### Treatment Plan 1. **Contraceptive counseling using a tiered approach (ACOG/AAP recommended):** - **Tier 1 — Most effective (LARC methods):** Etonogestrel implant (Nexplanon) and intrauterine devices (hormonal: Mirena/Kyleena/Liletta; copper: Paragard). Failure rate <1%. Recommended as first-line for adolescents by ACOG and AAP. - **Tier 2 — Effective:** Injectable (DMPA), combined hormonal methods. Note: **Combined hormonal contraceptives (pill, patch, ring) are CONTRAINDICATED in this patient due to migraine with aura** (USMEC Category 4 — unacceptable health risk due to 2-4x increased risk of ischemic stroke). - **Tier 3 — Moderately effective:** Progestin-only pills, condoms, other barrier methods. - Patient's preference for the etonogestrel implant is an excellent choice given her history of migraine with aura — progestin-only methods are USMEC Category 1 (no restriction) for migraine with aura. 2. **Etonogestrel subdermal implant (Nexplanon) insertion:** - **Timing:** Can be inserted today (Quick Start method) — she is on Day 14 of her cycle, pregnancy test negative, last unprotected intercourse 4 days ago. Use backup method (condoms) for 7 days after insertion. - **Procedure:** Implant placed subdermally in the medial aspect of the non-dominant upper arm, 8-10 cm above the medial epicondyle, in the sulcus between biceps and triceps. Local anesthesia with 1% lidocaine. Palpate implant after insertion. - **Duration:** Effective for up to 3 years (FDA-approved; evidence supports efficacy for up to 5 years) - **Side effects counseled:** Irregular bleeding (most common, especially in first 6 months), amenorrhea (in approximately 22%), headache, mood changes, weight change (average 2-3 lbs over 3 years, not clinically significant) - **Efficacy:** >99.9% — the most effective reversible contraceptive available 3. **Emergency contraception discussion:** - Unprotected intercourse 4 days ago at Day 14 (likely near ovulation): Ulipristal acetate (Ella) 30 mg single dose is the most effective oral emergency contraception up to 5 days post-intercourse and is effective closer to ovulation than levonorgestrel - Alternatively, copper IUD (Paragard) is the most effective emergency contraception (>99%) and can be placed up to 5 days after unprotected intercourse - If she chooses ulipristal acetate today and the implant, the implant should be placed starting 5 days after ulipristal (as progestins may decrease ulipristal efficacy); alternatively, if she accepts the small residual pregnancy risk, the implant can be placed today 4. **STI screening and prevention:** - Chlamydia and gonorrhea screening (NAAT, urine): obtained today — recommended annually for all sexually active females <25 years - HIV and syphilis screening: obtained today - Hepatitis B immunity: verify immunization records - HPV vaccination: verify status (Gardasil 9; if not completed, administer catch-up series) - Counsel on dual protection: LARC prevents pregnancy but NOT STIs; emphasize consistent condom use for STI prevention - Provide condoms at the visit 5. **Confidentiality and legal considerations:** - Document the patient's capacity to provide informed consent (mature minor doctrine; state-specific minor consent laws for reproductive health apply) - Ensure confidential billing: discuss implications for explanation of benefits (EOB) if on parents' insurance; explore Title X family planning clinic or state-funded program if insurance confidentiality cannot be guaranteed - Document HEADSS assessment and screening for coercion, trafficking, and abuse (negative in this case) - Address the age-of-consent question: both partners are 16 and 17 (within the Romeo-and-Juliet exemption range in most jurisdictions; no mandatory reporting obligation in most states for consensual sexual activity between peers of similar age) 6. **Follow-up:** - Return in 3 months to review implant tolerability, bleeding pattern, and STI results - Annual STI screening - Repeat pregnancy test if amenorrheic and concerned, or if symptoms develop - Open invitation to return for any concerns without an appointment requirement (adolescent-friendly access) ### Key Learning Points - Migraine with aura is an absolute contraindication (USMEC Category 4) to all estrogen-containing contraceptives (combined oral contraceptive pills, combined patch, combined vaginal ring) due to a 2-4x increased risk of ischemic stroke; progestin-only methods (implant, hormonal IUD, POP, DMPA) are safe (Category 1-2). - LARC methods (implants and IUDs) are recommended as first-line contraception for adolescents by ACOG, AAP, and WHO because they eliminate adherence barriers and have the lowest failure rates (<1%); myths about IUD use in nulliparous adolescents are unfounded. - A pelvic examination is NOT required prior to initiating any form of contraception, including IUDs and implants; this is a common misconception that creates barriers to adolescent contraceptive access. - Confidentiality is the cornerstone of adolescent reproductive healthcare; all US states allow minors to consent to contraceptive services, and providers should proactively address confidentiality concerns including insurance billing (EOB) and electronic health record access by parents. - The Quick Start method (initiating contraception on the day of the visit regardless of cycle day) improves method uptake and reduces the risk of pregnancy between counseling and initiation; a negative pregnancy test and backup contraception for 7 days are sufficient.